Translational Development Acquisition Corp. issued a press release on June 22, 2026, disclosing shareholder redemption results following a June 17, 2026, vote to extend the deadline for completing an initial business combination. The filing also provides information regarding the company's proposed business combination with ProLogium Holding Inc. Translational Development Acquisition Corp. is a special purpose acquisition company.

Translational Development Acquisition Corp. shareholders approved a special resolution to extend the deadline for completing a business combination from June 24, 2026, to June 24, 2027. This extension can occur up to twelve times in one-month increments. The company also amended its Investment Management Trust Agreement to permit these extensions, requiring a deposit of the lesser of $200,000 or $0.03 per outstanding public share into the trust account for each extension. Following the meeting, 2,598,697 Class A ordinary shares were redeemed for cash at approximately $10.70 per share, totaling roughly $27,817,434. Translational Development Acquisition Corp. is a blank check company focused on pursuing business combinations.

On June 12, 2026, Translational Development Acquisition Corp. issued 4,657,499 Class A ordinary shares to TDAC Partners LLC. This issuance resulted from the conversion of an equivalent number of Class B ordinary shares held by the Sponsor. The transaction generated no cash proceeds and did not impact the company's trust account or the per-share redemption value, which was approximately $10.69. Following this conversion, 21,907,499 Class A ordinary shares and one Class B ordinary share are outstanding. The company is a special purpose acquisition company.